



Construction of pIG.NEO



Overview of available adenovirus packaging constructs and assessment of their capacity to transform primary kidney cells



*average of 5 plates 21 days after transelection

FIG. 6

Western blotting analysis of A549 clones transfected with pIG.E1A.NEO and PER clones (HER cells transfected with pIG.E1A.E1B)




FIG. 7

Southern blot analyses of 293, 911 and PER cell lines




FIG. 8

Transfection efficiency of PER.C3, PER.C5, PER.C6 and 911 cells. Cells were cultured in 6-well plates and transfected (n=2) with 5 μg pRSV.lasZ by calcium-phosphate co-precipitation. Forty-eight hours later the cells were stained with X-GAL. The mean percentage of blue cells is shown.




FIG. 9

Construction of pMLP1.TK





FIG. 10

10074000.001WDN

New recombinant adenoviruses and packaging constructs without sequence overlap




Packaging system based on primary cells

FIG. I IA

HOUSENG, DESERVED IN

New recombinant adenoviruses and packaging constructs without sequence overlap



Packaging system based on established cell lines: transfection FIG. I IB with E1a and selection with G418




FIG. 12




FIG. 13

Replication of Adenovirus




FIG. 14

The potential hairpin conformation of a single—stranded DNA molecule that contains the HP/asp sequences used in these studies. Restriction with the restriction endonucleases <code>Asp7181</code> of plasid pICLHa, containing the annealed oligonucleotide pair HP/asp1 en HP/asp2 will yield a linear double—stranded DNA fragment. In cells in which the required adenovirus genes are present, replication can initiate at the terminus that contains the ITR sequence. During the chain elongation, the one of the strands will be displaced. The terminus of the single—stranded displaced—strand molecule can adopt the conformation depicted above. In this conformation the free 3'—terminus can serve as a primer for the cellular and/or adenovirus DNA polymerase, resulting in conversion of the displaced strand in a double—stranded form.

5'-GTACACTGACCTAGTGCCGCCCGGGCA ||||||||||||| A 3'-GATCACGGCGGGCCCGA




FIG. 16




FIG. 17




FIG. 18




FIG. 19

Cloned adenovirous fragments




FIG. 20

Adapter plasmid pAd5/L420-HSA




FIG. 21

Adapter plasmid pAd5/CLIP





FIG. 22

EDET 20 8994/001



Minimal adenovirus vector pMV/L420H





FIG. 24






FIG. 26A





FIG. 26C

nesni AMO





Average percentage CPE efficiency: 86 %


FIG. 27


	Average titer 0.8 ±0.7 x 10 ⁹ pfu/ml								FIG. 28					
Insert kb	3.6	3.5	3.5	3.2	2.2	2.0	1.7	1.4	.550	.511	.434	.412	.104	
Gene	• ceNOS	• hTERT	 hTERT D712A 	• lacZ	• hCAT1	• GLVR2	• Luc	• SOD3	• MAX1	• hVEGF121	• hIL3	• UBC9	• ANG1-7	

% wells producing functional virus










#days of infection and MOI

FIG. 32



Percentage CPE (%)




FIG. 34A




FIG. 34B






FIG. 34C












FIG. 34G












FIG. 34M

Relative amounts of wells with CPE after transfection of PER.C6/E2A cells with pCLIP-LacZ and the adapter plasmid pIPspAdapt2.

Transfection of pIPspAdapt2 to PER.06/E2A





FIG. 34N






FIG. 36A




FIG. 36B

EXAMPLE 21 384 WELL PLATE IN PROGRESS




FIG. 37D

FIG. 37C

Time (days)

Time (days)

Medium changed 7 days after transfection




FIG. 38A




FIG. 38B

Propagation 7 days after transfection









FIG. 38C

















FIG. 44





Infection of human primary pre-adipocytes using



V






Figure 49

Adipocyte differentiation
Primary human mesenchymal stem cells







Nile Red: Lipid droplets

Hoechst 33342: nuclei

H5-24: adenoviraly mediated expression of CIDEB does not induce any cell death

H5-1 DNA sequence (SEQ ID NO:14)

1	GCCCACGCGT	CCGGTTTTCT	ACTTTGCCAC	AGATTATCTT	GTACAGCCTT	TTATGGACCA
61	ATTAGCATTC	CATCAATTTT	ATATCTAGCA	TATTTGCGGT	TAGAATCCCA	TGGATGTTTC
121	TTCTTTGACT	ATAACAAAAT	CTGGGGAGGA	CAAAGGTGAT	TTTCCTGTGT	CCACATCTAA
181	CAAAGTCAAG	ATTCCCGGCT	GGACTTTTGC	AGCTTCCTTC	CAAGTCTTCC	TGACCACCTT
241	GCACTATTGG	ACTTTGGAAG	GAGGTGCCTA	TAGAAAACGA	TTTTGAACAT	ACTTCATCGC
301	AGTGGACTGT	GTCCCTCGGT	GCAGAAACTA	CCAGATTTGA	GGGACGAGGT	CAAGGAGATA
361	TGATAGGCCC	GGAAGTTGCT	GTGCCCCATC	AGCAGCTTGA	CGCGTGGTCA	CAGGACGATT
421	TCACTGACAC	TGCGAACTCT	CAGGACTACC	GTTACCAAGA	GGTTAGGTGA	AGTGGTTTAA
481	ACCAAACGGA	ACTCTTCATC	TTAAACTACA	CGTTGAAAAT	CAACCCAATA	ATTCTGTATT
541	AACTGAATTC	TGAACCTTTC	AGGAGGTACT	GTGAGGAAGA	GCAGGCACCA	GCAGCAGAAT
601	GGGGAATGGA	GAGGTGGGCA	GGGGTTCCAG	CTTCCCTTTG	ATTTTTTGCT	GCAGACTCAT
661	CCTTTTTAAA	TGAGACTTGT	TTTCCCCTCT	CTTTGAGTCA	AGTCAAATAT	GTAGATTGCC
721	TTTGGCAATT	CTTCTTCTCA	AGCACTGACA	CTCATTACCG	TCTGTGATTG	CCATTTCTTC
781	CCAAGGCCAG	TCTGAACCTG	AGGTTGCTTT	ATCCTAAAAG	TTTTAACCTC	AGGTTCCAAA
841	TTCAGTAAAT	TTTGGAAACA	GTACAGCTAT	TTCTCATCAA	TTCTCTATCA	TGTTGAAGTC
901	AAATTTGGAT	TTTCCACCAA	ATTCTGAATT	TGTAGACATA	CTTGTACGCT	CACTTGCCCC
961	AGATGCCTCC	TCTGTCCTCA	TTCTTCTCTC	CCACACAAGC	AGTCTTTTTC	TACAGCCAGT
1021	AAGGCAGCTC	TGTCGTGGTA	GCAGATGGTC	CCATTATTCT	AGGGTCTTAC	TCTTTGTATG
1081	ATGAAAAGAA	TGTGTTATGA	ATCGGTGCTG	TCAGCCCTGC	TGTCAGACCT	TCTTCCACAG
1141	CAAATGAGAT	GTATGCCCAA	AGACGGTAGA	ATTAAAGAAG	AGTAAAATGG	CTGTTGAAGC
1201	аааааааа	AAAAA				

H5-24 DNA sequence (SEQ ID NO:16)

1	GTCGACCCAC	GCGTCCGCGC	CTGCAGAAGG	TTGACTGCGT	GGTAGGGGGC	CCAGAGCAAG
61	CCGAAGGCAA	GCACGATGGC	GCTCACCAGC	CGGCCCACCC	GCGCCCCGTG	CCGCCCGGAG
121	CCCCAGCGGG	CGCCCGCAG	CCGTGCCAGC	GTCACGCTGT	AGCAGCCGAG	CATCAGCCCG
181	AAAGGAAGCA	CGAAAGCGGT	GGCGGTAGAC	GGCGGCCGGG	ACGGCGAGCA	ACAGGGCGGC
241	CAGCCAGACC	GCCAGCAGCA	GGCGGCGGGC	CAGGGCCGGG	CTGCGCAGCC	GAGGCGCCAG
301	GAAGGGGCGG	GTGACTGCGA	GGCAGCGCTG	CAGGCTGAGC	AGGCCGGTGA	GCAGCACGCT
361	GGCGTACATG	CTGAGCGCGC	ACACGTAGTA	CACCGCCTTG	CAGCCCGCCT	GGCCCAGCGG
421	CCAGGCCTGC	CGGGTCAGGA	AGGCCACAAA	GAGCGGCGTG	AGCAGCAGCA	CCGCGCCGTC
481	GGCCAGCGCC	AGGTGCAGCA	CAAGCGTGGC	CGCCAGCGGT	CGCCCCGTG	CAGGCCGCCA
541	GCCCGCCAAG	CTCCACACCA	CGAAGCCGTT	GCCAGGCAGC	CCCAGCAGCG	CCGCCAGCAG
601	CAGGAAGGCT	GTGCCTGTGG	CCCGCGAAGT	CTTCCAGCTC	AGCAGTGTCT	CGTTCCCTGG
661	GGGACGGTAG	CAGACCGACA	TCCTTCTGGG	CCTACAGGAC	ACAGAAAAAA	AGTGGGGAAG
721	CTGGGGGACC	CCTACAAGGA	TCCTTGGCAG	GAAAGCAGGG	ATTGTGTTCA	TTTGAGGGTT
781	TCACTGTCAG	TGAGAGTCTC	AGCTTCCATG	CAACTGTCCA	TCACGGCTGC	AACTGAAATC
841	AGAGCTGGGA	CACAGCGCAC	CAGAAGCTAA	AGTCTTGATG	CCATCAAAGG	ACATCCCTGC
901	CCCATTCACA	TCTCTGTCAC	GTCCACTAAT	CGGCAAAAGG	AGAAAAGTGA	GAGAAGATGA
961	CCTAAGTGTG	ACTGCAGCAG	GCAGCTCTGG	AAAATGAAGC	CAGAGCAGTG	AGCCAGCCCC
1021	TCCTCCGACC	AAGGAGGAAG	GAAAGAGCAG	CCCCAGCACA	GGAGAGAACC	ACCCAGCCCA
1081	GAAGTTCCAG	GGAAGGAACT	CTCCGGTCCA	CCATGGAGTA	CCTCTCAGCT	CTGAACCCCA
1141	GTGACTTACT	CAGGTCAGTA	TCTAATATAA	GCTCGGAGTT	TGGACGGAGG	GTCTGGACCT
1201	CAGCTCCACC	ACCCCAGCGA	CCTTTCCGTG	TCTGTGATCA	CAAGCGGACC	ATCCGGAAAG
	GCCTGACAGC					
1321	ATGGAGTGCT	AACCCTGGTG	CTAGAGGAGG	ATGGAACTGC	AGTGGACAGT	GAGGACTTCT
	TCCAGCTGCT					
	CTACAAGGAG					
1501	ACATCGCCCG	ATTCACCTTT	GACGTGTACA	AGCAAAACCC	TCGAGACCTC	TTTGGCAGCC
1561	TGAATGTCAA	AGCCACATTC	TACGGGCTCT	ACTCTATGAG	TTGTGACTTT	CAAGGACTTG
	GCCCAAAGAA					
1681	GCCATATGTT	GCTGGGAATT	TCCTCCACCC	TTCGTCATGC	AGTGGAGGGG	GCTGAGCAGT
1741	GGCAGCAGAA	GGGCCGCCTC	CATTCCTACT	AAGGGGCTCT	GAGCTTCTGC	CCCCAGAATC
1801	ATTCCAACCG	ACCCACTGCA	AAGACTATGA	CAGCATCAAA	TTTCAGGACC	TGCAGACAGT
1861	ACAGGCTAGA	TAACCCACCC	AATTTCCCCA	CTGTCCTCTG	ATCCCCTCGT	GACAGAACCT
1921	TTCAGCATAA	CGCCTCACAT	CCCAAGTCTA	TACCCTTACC	TGAAGAATGC	TGTTCTTTCC
1981	TAGCCACCTT	TCTAGCCTCC	CACTTGCCCT	GAAAGGCCAA	GATCAAGATG	TCCCCCAGGC
2041	ATCTTGATCC	CAGCCTGACT	GCTGCTACAT	CTAATCCCCT	ACCAATGCCT	CCTGTCCCTA
2101	AACTCCCCAG	CATACTGATG	ACAGCCCTCT	CTGACTTTAC	CTTGAGATCT	GTCTTCATAC
2161	CCTTCCCCTC	AAACTAACAA	AAACATTTCC	AATAAAAATA	TCAAATATTT	АААААААА
2221	AAAAAAAGGG	CGGCCGC				

H5-24 ORF4 Amino Acid sequence (SEQ ID NO:15)

- 1 MEYLSALNPS DLLRSVSNIS SEFGRRVWTS APPPQRPFRV CDHKRTIRKG
- 51 LTAATRQELL AKALETLLLN GVLTLVLEED GTAVDSEDFF QLLEDDTCLM
- 101 VLQSGQSWSP TRSGVLSYGE GRERPKHSKD IARFTFDVYK QNPRDLFGSL
- 151 NVKATFYGLY SMSCDFQGLG PKKVLRELLR WTSTLLQGLG HMLLGISSTL
- 201 RHAVEGAEQW QQKGRLHSY 219

Region 1 of H5-24 Complementary to BLTR2 DNA sequence (SEQ ID NO:17)

18 CGC CTGCAGAAGG TTGACTGCGT GGTAGGGGGC CCAGAGCAAG

- 61 CCGAAGGCAA GCACGATGGC GCTCACCAGC CGGCCCACCC GCGCCCCGTG CCGCCCGGAG
- 121 CCCCAGCGGG CGCCCCGCAG CCGTGCCAGC GTCACGCTGT AGCAGCCGAG CATCAGCCCG
- 181 AAAGGAAGCA CGAAAGCGGT 200

Region 2 of H5-24 Complementary to BLTR2 DNA sequence (SEQ ID NO:18)

		198 GGT	GGCGGTAGAC	GGCGGCCGGG	ACGGCGAGCA	ACAGGGCGGC	
241	CAGCCAGACC	GCCAGCAGCA	GGCGGCGGC	CAGGGCCGGG	CTGCGCAGCC	GAGGCGCCAG	
301	GAAGGGGCGG	GTGACTGCGA	GGCAGCGCTG	CAGGCTGAGC	AGGCCGGTGA	GCAGCACGCT	
361	GGCGTACATG	CTGAGCGCGC	ACACGTAGTA	CACCGCCTTG	CAGCCCGCCT	GGCCCAGCGG	
421	CCAGGCCTGC	CGGGTCAGGA	AGGCCACAAA	GAGCGGCGTG	AGCAGCAGCA	CCGCGCCGTC	
481	GGCCAGCGCC	AGGTGCAGCA	CAAGCGTGGC	CGCCAGCGGT	CGCCCCGTG	CAGGCCGCCA	
541	GCCCGCCAAG	CTCCACACCA	CGAAGCCGTT	GCCAGGCAGC	CCCAGCAGCG	CCGCCAGCAG	
601	CAGGAAGGCT	GTGCCTGTGG	CCCGCGAAGT	CTTCCAGCTC	AGCAGTGTCT	CGTTCCCTGG	
661	GGGACGGTAG	CAGACCGACA	TCCTTCTGGG	CCTACAGG 69	98		

Alignment of SEQ ID NO:17 with DNA sequence complementary to BLTR2 sequence. SEQ ID NO:17 is 100% identical to antisense BLTR2 DNA.

	cgcctgcagaaggttgactgcgtggtaggggcccagagcaagccgaaggcaagcacgat	
Antisense 2455 BLTR2	cgcctgcagaaggttgactgcgtggtagggggcccagagcaagccgaaggcaagcacgat	2396
	ggcgctcaccagccggcccacccgcgccccgtgccgcccggagccccagcgggccccg	
Antisense 2395 BLTR2	ggcgctcaccagccggcccaccgcgccccgtgccccggagccccagcgggcgccccg	2336
SEQ ID NO:17 138	cagecgtgccagegtcacgetgtagcagccgagcatcagcccgaaaggaagcacgaaage	197
Antisense 2335 BLTR2	cagccgtgccagcgtcacgctgtagcagccgagcatcagcccgaaaggaagcacgaaagc	2276
SEQ ID NO:17 198	ggt 200 	
Antisense 2275	ggt 2273	

BLTR2

Alignment of SEQ ID NO:18 with DNA sequence complementary to BLTR2 sequence. SEQ ID NO:18 is 100% identical to antisense BLTR2 DNA.

-	g ggtggcggtagacggcgggccgggacggcgagcagcagggggccagccagccagccagcag	
Antisense 219 BLTR2	i ggtggcggtagacggcggccgggacggcgagcaacagggcggccagccagccagca	2136
SEQ ID NO:18 25	g caggeggegggeeagggeegggetgegeageegaggegaggeaggaagggggggg	317
Antisense 213 BLTR2	geaggeggegggeeagggeegggetgegeageegaggegaggeeaggaagggggggg	2076
	g cgaggcagcgctgcaggctgagcaggccggtgagcagcagctggcgtacatgctgagcg	
Antisense 207 BLTR2	5 cgaggcagcgctgcaggctgagcaggcoggtgagcagcacgctggcgtacatgctgagcg	2016
SEQ ID NO:18 37	3 cgcacacgtagtacaccgccttgcagcccgcctggcccagcggccaggccaggcctgccgggtca	437
Antisense 201 BLTR2	5 cgcacacgtagtacaccgccttgcagcccgcctggcccagcggccaggcctgccgggtca	1956
	ggaaggccacaaagagcgcgtgagcagcagcaccgcgccgtcggccagcgccaggtgca	
Antisense 195 BLTR2	5 ggaaggccacaaagagcggcgtgagcagcagcaccgccgtcggccagcgccaggtgca	1896
	8 gcacaagcgtggccgccagcggtcgcccccgtgcaggccgccagcccgccaagctccaca	
Antisense 189 BLTR2	5 gcacaagogtggoogocagoggtogoocogtgoaggoogocagooogocaagotocaca	1836
SEQ ID NO:18 55	8 ccacgaagccgttgccaggcagccccagcagcgccgccagcagcaggaaggctgtgcctg	617
Antisense 183 BLTR2	5 coacgaagccgttgccaggcagccccagcagcgccgccagcagcaggaaggctgtgcctg	1776
	8 tggcccgcgaagtcttccagctcagcagtgtctcgttccctgggggacggtagcagaccg	
Antisense 177 BLTR2	5 tggcccgcgaagtettecageteageagtgtetegttecetggggggaeggtageagaeeg	1716
SEQ ID NO:18 67	8 acateettetgggeetacagg 698	
Antisense 171 BLTR2	5 acatcettetgggcetacagg 1695	